Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Vomiting 6Nausea 6Breast Neoplasms 3Neoplasms 2Hematologic Neoplasms 2Weight Loss 1Sedentary Behavior 1Postoperative Nausea and Vomiting 1Neoplasms, Plasma Cell 1Muscular Atrophy 1Multiple Endocrine Neoplasia Type 1 1Lymphoma 1Insulin Resistance 1Hyperlipidemias 1Hyperglycemia 1Delirium 1Child Nutrition Disorders 1Cachexia 1Anorexia 1Advanced Cancer 1

Interventions

Haloperidol 2Vitamin E 1Surveys and Questionnaires 1Sodium Chloride 1Sevoflurane 1Propofol 1Pemetrexed 1Paclitaxel 1Olanzapine 1Neoadjuvant Therapy 1Mental Status and Dementia Tests 1Melatonin 1Injections 1Inhalation 1Donepezil 1Dexmedetomidine 1Anesthesia, Spinal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Delirium × Olanzapine × Clear all
NCT01539733 2017-04-07

Early Recognition and Optimal Treatment of Delirium in Patients With Advanced Cancer

Amsterdam UMC, location VUmc

Phase NA Completed
101 enrolled

Delirium

Data powered by HemOnc (CC BY 4.0) Colophon âš¡